Anti-cancer flower power

Aug 25, 2008

Could a substance from the jasmine flower hold the key to an effective new therapy to treat cancer? Prof. Eliezer Flescher of The Sackler Faculty of Medicine, Tel Aviv University thinks so. He and his colleagues have developed an anti-cancer drug based on a decade of research into the commercial applications of the compound Jasmonate, a synthetic compound derived from the flower itself. Prof. Flescher began to research the compound about a decade ago, and with his recent development of the drug, his studies have now begun to bear meaningful fruit.

"Acetylsalicylic acid (aspirin) is based on a plant stress hormone," says Prof. Flescher. "I asked myself, 'Could there be other plant stress hormones that have clinical efficacy?' While various studies have suggested that aspirin can prevent cancer, especially colon cancer, I realized that there could be a chance to find a potent plant hormone that could fight cancer even better. I pinpointed jasmonate."

Both blood cancers and solid tumors seem to be responsive to the jasmonate compound, known also as methyl jasmonate. Prof. Flescher refers to it as the "jasmonate scaffold," a basis for developing a series of chemical derivatives. In terms of bioavailability and safety, early first-in-man studies have proven successful, and Prof. Flescher is hopeful that an anti-cancer drug based on jasmonate could be on the shelf in America within four years through the activity of Sepal-Pharma which licensed his research from Ramot, the technology transfer arm of Tel Aviv University.

Normally drug development takes much longer. "The jasmonate compound is used widely in agriculture and in cosmetics," says Prof. Flescher. "Proven to be non-toxic, it has the same regulatory status as table salt. That and the fact we are working on a natural chemical gives us a good starting point for launching a new drug."

Other research groups are taking notice. Since Prof. Flescher started publishing papers on jasmonate (most recently in the academic journal Oncogene), six new research groups around the world have initiated research on the subject.

Peer commentary in Oncogene is positive about Prof. Flescher's promising research. "Methyl jasmonate," says the commentary, "has already been shown to have selective anticancer activity in preclinical studies, and this finding may stimulate the development of a novel class of small anticancer compounds."

Source: American Friends of Tel Aviv University

Explore further: New survey shows 36-percent increase in pediatric patients treated with proton therapy

Related Stories

Bugs and slugs ideal houseguests for seagrass health

6 hours ago

Marine "bugs and slugs" make ideal houseguests for valuable seagrass ecosystems. They gobble up algae that could smother the seagrass, keeping the habitat clean and healthy. That's according to results from ...

Recommended for you

Vortex device makes for better cancer treatments

May 22, 2015

A South Australian invention, responsible for unboiling an egg, has been used to produce a four-fold increase in efficacy of carboplatin, a commonly used drug for ovarian, lung and other cancer. ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.